Immune response to SARS-CoV-2 vaccination in relation to peripheral immune cell profiles among patients with multiple sclerosis receiving ocrelizumab

BACKGROUND: Vaccination has proven to be effective in preventing SARS-CoV-2 transmission and severe disease courses. However, immunocompromised patients have not been included in clinical trials and real-world clinical data point to an attenuated immune response to SARS-CoV-2 vaccines among patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Räuber, Saskia, Korsen, Melanie, Huntemann, Niklas, Rolfes, Leoni, Müntefering, Thomas, Dobelmann, Vera, Hermann, Alexander M, Kölsche, Tristan, von Wnuck Lipinski, Karin, Schroeter, Christina B, Nelke, Christopher, Regner-Nelke, Liesa, Ingwersen, Jens, Pawlitzki, Marc, Teegen, Bianca, Barnett, Michael Harry, Hartung, Hans-Peter, Aktas, Orhan, Albrecht, Philipp, Levkau, Bodo, Melzer, Nico, Ruck, Tobias, Meuth, Sven G, Kremer, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Multiple Sclerosis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8889453/
https://www.ncbi.nlm.nih.gov/pubmed/35193952
http://dx.doi.org/10.1136/jnnp-2021-328197

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8889453/
https://www.ncbi.nlm.nih.gov/pubmed/35193952
http://dx.doi.org/10.1136/jnnp-2021-328197

Ejemplares similares